Maspero, Jorge
Agache, Ioana Octavia
Kamei, Tadashi
Yoshida, Makoto
Boone, Bryan
Felser, James M.
Kawakami, Fernando
Knorr, Barbara
Lawrence, David
Lehmann, Thomas
Wang, Wei
Pedinoff, Andrew J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial
https://doi.org/10.1186/s12931-021-01904-8
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 16 August 2021
Accepted: 23 November 2021
First Online: 11 December 2021
Declarations
:
: The study protocol, amendments, informed consent forms, and other relevant documents were reviewed by the independent ethics committee or institutional review board for each centre. The studies were designed, implemented, and reported in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E6 Guideline for Good Clinical Practice.
: Not applicable.
: I.O.A. reports their role of Associate Editor of Allergy, and Clinical and Translational Allergy. B.B., J.F. and B.K. report personal fees from employment within Novartis Pharmaceuticals Corporation outside the submitted work, as well as being stock/shareholders in Novartis. F.K., D.L. and T.L. report personal fees from employment within Novartis Pharma AG outside the submitted work, as well as being stock/shareholders in Novartis. J.M. reports grants and personal fees from Novartis, Astrazeneca, Sanofi, MSD and Immunotek, personal fees from Uriach, and grants and non-financial support from GSK, outside the submitted work. A.P. reports employment as a consultant within Novartis Pharmaceutical Corporation during the conduct of the study. W.W. reports personal fees from employment within Novartis Institutes for Biomedical Research Co., Ltd, Shanghai, outside the submitted work. T.K. and M.Y. declare they have no competing interests.